Department of Neurology, Saint Louis, MO, USA.
Mol Neurodegener. 2013 Apr 19;8:13. doi: 10.1186/1750-1326-8-13.
The APOE4 allele variant is the strongest known genetic risk factor for developing late-onset Alzheimer's disease. The link between apolipoprotein E (apoE) and Alzheimer's disease is likely due in large part to the impact of apoE on the metabolism of amyloid β (Aβ) within the brain. Manipulation of apoE levels and lipidation within the brain has been proposed as a therapeutic target for the treatment of Alzheimer's disease. However, we know little about the dynamic regulation of apoE levels and lipidation within the central nervous system. We have developed an assay to measure apoE levels in the brain interstitial fluid of awake and freely moving mice using large molecular weight cut-off microdialysis probes.
We were able to recover apoE using microdialysis from human cerebrospinal fluid (CSF) in vitro and mouse brain parenchyma in vivo. Microdialysis probes were inserted into the hippocampus of wild-type mice and interstitial fluid was collected for 36 hours. Levels of apoE within the microdialysis samples were determined by ELISA. The levels of apoE were found to be relatively stable over 36 hours. No apoE was detected in microdialysis samples from apoE KO mice. Administration of the RXR agonist bexarotene increased ISF apoE levels while ISF Aβ levels were decreased. Extrapolation to zero-flow analysis allowed us to determine the absolute recoverable concentration of apoE3 in the brain ISF of apoE3 KI mice. Furthermore, analysis of microdialysis samples by non-denaturing gel electrophoresis determined lipidated apoE particles in microdialysis samples were consistent in size with apoE particles from CSF. Finally, we found that the concentration of apoE in the brain ISF was dependent upon apoE isoform in human apoE KI mice, following the pattern apoE2>apoE3>apoE4.
We are able to collect lipidated apoE from the brain of awake and freely moving mice and monitor apoE levels over the course of several hours from a single mouse. Our technique enables assessment of brain apoE dynamics under physiological and pathophysiological conditions and in response to therapeutic interventions designed to affect apoE levels and lipidation within the brain.
APOE4 等位基因变异是已知的最强的导致迟发性阿尔茨海默病的遗传风险因素。载脂蛋白 E(apoE)与阿尔茨海默病之间的联系很可能在很大程度上归因于 apoE 对大脑中淀粉样蛋白 β(Aβ)代谢的影响。apoE 水平的操纵和大脑中的脂质化已被提议作为治疗阿尔茨海默病的治疗靶点。然而,我们对中枢神经系统内 apoE 水平和脂质化的动态调节知之甚少。我们开发了一种使用大分子量截止微透析探针测量清醒和自由活动小鼠脑间质液中 apoE 水平的测定法。
我们能够使用体外人脑脊液(CSF)和体内小鼠脑实质的微透析从体外和体内回收 apoE。将微透析探针插入野生型小鼠的海马体,并收集 36 小时的间质液。通过 ELISA 测定微透析样本中的 apoE 水平。结果发现,在 36 小时内,apoE 水平相对稳定。apoE KO 小鼠的微透析样本中未检测到 apoE。RXR 激动剂 bexarotene 的给药增加了 ISF apoE 水平,同时降低了 ISF Aβ 水平。外推至零流分析使我们能够确定 apoE3 KI 小鼠脑 ISF 中绝对可回收 apoE3 的浓度。此外,通过非变性凝胶电泳分析微透析样本确定,微透析样本中的脂质化 apoE 颗粒在大小上与 CSF 中的 apoE 颗粒一致。最后,我们发现人类 apoE KI 小鼠脑 ISF 中的 apoE 浓度取决于 apoE 同工型,遵循 apoE2>apoE3>apoE4 的模式。
我们能够从清醒和自由活动的小鼠脑中收集脂质化 apoE,并能够在单个小鼠中监测几个小时内的 apoE 水平。我们的技术使我们能够在生理和病理生理条件下以及在针对影响大脑中 apoE 水平和脂质化的治疗干预措施的反应中评估大脑 apoE 动力学。